BioThrust develops innovative bioreactor systems for optimized production of novel medical gene and cell therapies. The core innovation is the proprietary BioThrust membrane module, which enables the world's first completely bubble-free aeration of bioreactors. The production of the latest drugs requires the cultivation of cells in bioreactors. In the process, these cells must be supplied with oxygen. However, the current supply based on bubbles leads to high shear forces that damage the cells and thus reduce the output of the process.
The completely bubble-free aeration of the BioThrust membrane module solves these problems and serves as an "artificial lung" for the cells, just like in the human body. Due to these significantly improved conditions, the process output can be increased by up to 250%. The goal is to enable the cost-effective production of cell and gene therapies with this disruptive production technology.